Evan David Seigerman
Stock Analyst at BMO Capital
(3.49)
# 929
Out of 5,122 analysts
55
Total ratings
52.08%
Success rate
5.93%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Evan David Seigerman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MRK Merck & Co. | Upgrades: Outperform | $82 → $130 | $106.06 | +22.57% | 5 | Dec 18, 2025 | |
| REGN Regeneron Pharmaceuticals | Maintains: Outperform | $725 → $850 | $773.94 | +9.83% | 9 | Dec 4, 2025 | |
| AMGN Amgen | Maintains: Outperform | $335 → $372 | $328.69 | +13.18% | 5 | Dec 3, 2025 | |
| NVO Novo Nordisk | Maintains: Market Perform | $50 → $46 | $51.22 | -10.19% | 8 | Nov 25, 2025 | |
| REPL Replimune Group | Upgrades: Market Perform | $2 → $11 | $9.82 | +12.02% | 5 | Nov 3, 2025 | |
| ABBV AbbVie | Maintains: Outperform | $215 → $240 | $229.74 | +4.47% | 8 | Sep 12, 2025 | |
| NGNE Neurogene | Maintains: Outperform | $22 → $26 | $22.11 | +17.59% | 2 | Jun 12, 2025 | |
| MRUS Merus | Maintains: Outperform | $96 → $110 | $89.00 | +23.60% | 1 | May 23, 2025 | |
| ACAD ACADIA Pharmaceuticals | Maintains: Outperform | $24 → $28 | $26.70 | +4.87% | 2 | May 19, 2025 | |
| ARVN Arvinas | Maintains: Outperform | $20 → $10 | $11.73 | -14.75% | 1 | May 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $70 → $112 | $76.89 | +45.66% | 1 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $83 → $100 | $67.78 | +47.54% | 2 | Jun 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $33 → $36 | $24.99 | +44.06% | 4 | May 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $9 → $3 | $5.71 | -47.46% | 1 | May 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $369 → $396 | $1,079.75 | -63.32% | 1 | Sep 6, 2022 |
Merck & Co.
Dec 18, 2025
Upgrades: Outperform
Price Target: $82 → $130
Current: $106.06
Upside: +22.57%
Regeneron Pharmaceuticals
Dec 4, 2025
Maintains: Outperform
Price Target: $725 → $850
Current: $773.94
Upside: +9.83%
Amgen
Dec 3, 2025
Maintains: Outperform
Price Target: $335 → $372
Current: $328.69
Upside: +13.18%
Novo Nordisk
Nov 25, 2025
Maintains: Market Perform
Price Target: $50 → $46
Current: $51.22
Upside: -10.19%
Replimune Group
Nov 3, 2025
Upgrades: Market Perform
Price Target: $2 → $11
Current: $9.82
Upside: +12.02%
AbbVie
Sep 12, 2025
Maintains: Outperform
Price Target: $215 → $240
Current: $229.74
Upside: +4.47%
Neurogene
Jun 12, 2025
Maintains: Outperform
Price Target: $22 → $26
Current: $22.11
Upside: +17.59%
Merus
May 23, 2025
Maintains: Outperform
Price Target: $96 → $110
Current: $89.00
Upside: +23.60%
ACADIA Pharmaceuticals
May 19, 2025
Maintains: Outperform
Price Target: $24 → $28
Current: $26.70
Upside: +4.87%
Arvinas
May 5, 2025
Maintains: Outperform
Price Target: $20 → $10
Current: $11.73
Upside: -14.75%
Nov 5, 2024
Maintains: Outperform
Price Target: $70 → $112
Current: $76.89
Upside: +45.66%
Jun 7, 2024
Maintains: Outperform
Price Target: $83 → $100
Current: $67.78
Upside: +47.54%
May 2, 2024
Reiterates: Outperform
Price Target: $33 → $36
Current: $24.99
Upside: +44.06%
May 15, 2023
Maintains: Outperform
Price Target: $9 → $3
Current: $5.71
Upside: -47.46%
Sep 6, 2022
Maintains: Outperform
Price Target: $369 → $396
Current: $1,079.75
Upside: -63.32%